Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05279027 · ClinicalTrials.gov registry record · Early Phase 1
Zr89 + PET Companion Trial
A Early Phase 1 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
NCT05279027 is a Early Phase 1 study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 6 participants.
The verdict
NCT05279027, a Early Phase 1 study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
Study of Zirconium Zr 89 Crefmirlimab Berdoxa PET/CT as an imaging biomarker for assessing an early response to therapy in patients with advanced melanoma on immunotherapy and hydroxychloroquine. This study is a companion study to the "LIMIT Melanoma Trial." Patients with melanoma who are potentially eligible for the LIMIT Melanoma Trial and have at least one site of measurable disease based on RECIST 1.1 are potentially eligible. Associations with progression-free survival (PFS) and overall survival (OS) will be tested.
Interventions
- DRUG Zirconium Zr 89 Crefmirlimab Berdoxa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2022-03-08 |
| Est. Completion | 2025-05-06 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05279027
The ClinicalTrials.gov registry entry for NCT05279027 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Zirconium Zr 89 Crefmirlimab Berdoxa is the first listed.
NCT05279027 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05279027 about?
NCT05279027 is a clinical study titled "Zr89 + PET Companion Trial". Study of Zirconium Zr 89 Crefmirlimab Berdoxa PET/CT as an imaging biomarker for assessing an early response to therapy in patients with advanced melanoma on immunotherapy and hydroxychloroquine. This study is a companion study to the "LIMIT Melanoma Trial." Patients with melanoma who are potentiall...
What is the current status of trial NCT05279027?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2022-03-08. Estimated completion is 2025-05-06.
What interventions are being tested in trial NCT05279027?
The interventions under investigation include: Zirconium Zr 89 Crefmirlimab Berdoxa (DRUG).
Who is sponsoring clinical trial NCT05279027?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.